Modus Therapeutics announces first patient enrolled in the Phase I SEVUSMART clinical trial evaluating sevuparin in paediatric patients with severe malaria
STOCKHOLM, SWEDEN – 1 September 2022: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, announces the inclusion of the first patient and the start of SEVUSMART, an Imperial College London/Wellcome sponsored phase I clinical trial evaluating the Company’s proprietary drug sevuparin in paediatric patients with severe malaria.The SEVUSMART phase I trial will evaluate the safety and tolerability of escalating doses of sevuparin in up to 20 paediatric patients aged 3 months to 12 years presenting with severe malaria at